- Home
- DRMA vs ADTX Comparison
DRMA vs ADTX Comparison
Compare DRMA & ADTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRMA
- ADTX
- Stock Information
- Founded
- DRMA 2014
- ADTX 2017
- Country
- DRMA United States
- ADTX United States
- Employees
- DRMA N/A
- ADTX N/A
- Industry
- DRMA Biotechnology: Pharmaceutical Preparations
- ADTX Biotechnology: Pharmaceutical Preparations
- Sector
- DRMA Health Care
- ADTX Health Care
- Exchange
- DRMA Nasdaq
- ADTX Nasdaq
- Market Cap
- DRMA 3.5M
- ADTX 3.1M
- IPO Year
- DRMA 2021
- ADTX 2020
- Fundamental
- Price
- DRMA $5.48
- ADTX $1.04
- Analyst Decision
- DRMA Strong Buy
- ADTX
- Analyst Count
- DRMA 1
- ADTX 0
- Target Price
- DRMA $10.00
- ADTX N/A
- AVG Volume (30 Days)
- DRMA 28.3K
- ADTX 334.6K
- Earning Date
- DRMA 08-13-2025
- ADTX 08-14-2025
- Dividend Yield
- DRMA N/A
- ADTX N/A
- EPS Growth
- DRMA N/A
- ADTX N/A
- EPS
- DRMA N/A
- ADTX N/A
- Revenue
- DRMA N/A
- ADTX $12,051.00
- Revenue This Year
- DRMA N/A
- ADTX $15,768.94
- Revenue Next Year
- DRMA N/A
- ADTX N/A
- P/E Ratio
- DRMA N/A
- ADTX N/A
- Revenue Growth
- DRMA N/A
- ADTX N/A
- 52 Week Low
- DRMA $5.09
- ADTX $0.81
- 52 Week High
- DRMA $24.90
- ADTX $10,191.00
- Technical
- Relative Strength Index (RSI)
- DRMA 37.22
- ADTX 43.34
- Support Level
- DRMA $5.09
- ADTX $0.98
- Resistance Level
- DRMA $6.09
- ADTX $1.18
- Average True Range (ATR)
- DRMA 0.52
- ADTX 0.12
- MACD
- DRMA -0.09
- ADTX 0.01
- Stochastic Oscillator
- DRMA 20.22
- ADTX 48.42
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
About ADTX Aditxt Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.